Systemic and targeted therapy for advanced colon cancer

References

• Jemal A, Siegel R, Ward E et al. Cancer Statistics, 2007. CA Cancer J. Clin.57(1), 43–66 (2007).
   PubMed Web of Science ®Google Scholar
• Meyerhardt JA, Mayer RJ. Systemic therapy for colorectal cancer. N. Engl. J. Med.352(5), 476–487 (2005).
   PubMed Web of Science ®Google Scholar
• Greene FL, Page DL, Fleming ID et al. In: AJCC Cancer Staging Manual (6th Edition). Springer, New York, NY, USA (2002).
   Google Scholar
• O'Connell JB, Maggard MA, Ko CY. Colon cancer survival rates with the New American Joint Committee On Cancer Sixth Edition Staging. J. Natl Cancer Inst.96(19), 1420–1425 (2004).
   PubMed Web of Science ®Google Scholar
• Scheitauer W RH, Kornek GV, Sebesta C, Depisch D. Randomised comparison of combination chemotherapy plus supportive care alone in patients with metastatic colorectal cancer. BMJ306, 752–755 (1993).
   PubMedGoogle Scholar
• Cunningham D, Pyrhonen S, James RD et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet352(9138), 1413–1418 (1998).
   PubMed Web of Science ®Google Scholar
• Best PS, C Baughan, R Buchanan et al. Colorectal Meta-analysis Collaboration. Palliative chemotherapy for advanced or metastatic colorectal cancer. Cochrane Database Syst. Rev.1, CD001545 (2000).
   Google Scholar
• Sobrero A GA, Grossi F, Puglisi F et al. Mechanism of action of fluoropyrimidines: relevance to the new developments in colorectal cancer chemotherapy. Semin. Oncol.27(Suppl. 10), 72–77 (2000).
   PubMed Web of Science ®Google Scholar
• Zhang ZG HA, Rustum YM. Modulation of fluoropyrimidines: role of dose and schedule of leucovorin administration. Semin. Oncol.19(Suppl. 3), 10–15 (1992).
   PubMed Web of Science ®Google Scholar
• van Kuilenburg ABP, Muller EW, Haasjes J et al. Lethal outcome of a patient with a complete dihydropyrimidine dihydrogenase (DPD) deficiency after administration of 5-fluorouracil: frequency of the common IVS14+1G>A mutation causing DPD deficiency. Clin. Cancer Res.7(5), 1149–1153 (2001).
   PubMed Web of Science ®Google Scholar
• The Meta-Analysis Group in C. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: an updated meta-analysis. J. Clin. Oncol.22(18), 3766–3775 (2004).
   PubMed Web of Science ®Google Scholar
• Buyse M, Thirion P, Carlson RW et al. Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: a meta-analysis. Lancet356(9227), 373–378 (2000).
   PubMed Web of Science ®Google Scholar
• Hahn, RG, Moertel CG, Schutt AJ et al. A double-blind comparison of intensive course 5-fluorouracil by oral vs intravenous route in the treatment of colorectal carcinoma. Cancer35(4), 1031–1035 (1975).
   PubMed Web of Science ®Google Scholar
• Pentheroudakis G TC. The rational development of capecitabine from the laboratory to the clinic. AntiCancer Res.22, 3589–3596 (2002).
   PubMed Web of Science ®Google Scholar
• Meropol NJ. Oral fluoropyrimidines in the treatment of colorectal cancer. Eur. J. Cancer34(10), 1509–1513 (1998).
   PubMed Web of Science ®Google Scholar
• Sulkes A, Benner SE, Canetta RM. Uracil-ftorafur: an oral fluoropyrimidine active in colorectal cancer. J. Clin. Oncol.16(10), 3461–3475 (1998).
   PubMed Web of Science ®Google Scholar
• Schüller J, Cassidy J, Dumont E et al. Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients. Cancer Chemother. Pharmacol.45(4), 291–297 (2000).
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Twelves C, Cassidy J et al. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large Phase III study. J. Clin. Oncol.19(21), 4097–4106 (2001).
   PubMed Web of Science ®Google Scholar
• Hoff PM, Ansari R, Batist G et al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized Phase III study. J. Clin. Oncol.19(8), 2282–2292 (2001).
   PubMed Web of Science ®Google Scholar
• Mayer RJ. Oral versus intravenous fluoropyrimidines for advanced colorectal cancer: by either route, it’s all the same. J. Clin. Oncol.19(21), 4093–4096 (2001).
   PubMed Web of Science ®Google Scholar
• Cassidy J, Twelves C, Van Cutsem E et al. First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin. Ann. Oncol.13(4), 566–575 (2002).
   PubMed Web of Science ®Google Scholar
• Carmichael J, Popiela T, Radstone D et al. Randomized comparative study of tegafur/uracil and oral leucovorin versus parenteral fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J. Clin. Oncol.20(17), 3617–3627 (2002).
   PubMed Web of Science ®Google Scholar
• Douillard J-Y, Hoff PM, Skillings JR et al. Multicenter Phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J. Clin. Oncol.20(17), 3605–3616 (2002).
   PubMed Web of Science ®Google Scholar
• Raymond E FS, Woynarowski JM, Chaney SG. Oxaliplatin: mechanism of action and antineoplastic activity. Semin. Oncol.25, 4–12 (1998).
   PubMed Web of Science ®Google Scholar
• Rixe O, Ortuzar W, Alvarez M et al. Oxaliplatin, tetraplatin, cisplatin, and carboplatin: Spectrum of activity in drug-resistant cell lines and in the cell lines of the national cancer institute’s anticancer drug screen panel. Biochem. Pharmacol.52(12), 1855–1865 (1996).
   PubMed Web of Science ®Google Scholar
• Raymond E B-FC, Djelloul S et al. Antitiumor activity of oxaliplatin in combination with 5-fluorouracil-leucovorin and the thymidylate synthase inhibitor AG337 in human colon, breast, and ovarian cancers. Anticancer Drugs8, 876–885 (1997).
   PubMed Web of Science ®Google Scholar
• Rothenberg ML, Oza AM, Bigelow RH et al. Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a Phase III trial. J. Clin. Oncol.21(11), 2059–2069 (2003).
   PubMed Web of Science ®Google Scholar
• de Gramont A, Figer A, Seymour M et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J. Clin. Oncol.18(16), 2938–2947 (2000).
   PubMed Web of Science ®Google Scholar
• Raymond E, Faivre S, Chaney S, Woynarowski J et al. Cellular and molecular pharmacology of oxaliplatin. Mol. Cancer Ther.1(3), 227–235 (2002).
   PubMed Web of Science ®Google Scholar
• A. G. Oxaliplatin-safety profile: neurotoxicity. Semin. Oncol.30, 5–13 (2003).
   Google Scholar
• Armand JP BV, Raymond E et al. Oxaliplatin in colorectal cancer: an overview. Semin. Oncol.5(Suppl. 10), 96–104 (2000).
   Google Scholar
• Becouarn Y, Ychou M, Ducreux M et al. Phase II trial of oxaliplatin as first-line chemotherapy in metastatic colorectal cancer patients. Digestive Group of French Federation of Cancer Centers. J. Clin. Oncol.16(8), 2739–2744 (1998).
   PubMed Web of Science ®Google Scholar
• Giacchetti S, Perpoint B, Zidani R et al. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J. Clin. Oncol.18(1), 136(2000).
   PubMed Web of Science ®Google Scholar
• Grothey A, Deschler B, Kroening H et al. Phase III study of bolus 5-fluorouracil (5-FU)/folinic acid (FA) (Mayo) vs weekly high dose 24 h 5-FU infusion/FA + oxaliplatin (OXA) (FUFOX) in advanced colorectal cancer (ACRC). Proc. Am. Soc. Clin. Oncol.21 (2002) (Abstract 512).
   Google Scholar
• Comella P, Natale D, Farris A et al. Capecitabine plus oxaliplatin for the first-line treatment of elderly patients with metastatic colorectal carcinoma. Cancer104(2), 282–289 (2005).
   PubMed Web of Science ®Google Scholar
• Porschen R, Arkenau H-T, Kubicka S et al. Capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin: a randomized comparison in metastatic colorectal cancer – a final report of the AIO Colorectal Study Group. J. Clin. Oncol. (2007) (Epub ahead of print).
   PubMedGoogle Scholar
• Diaz-Rubio E, Tabernero J, Gomez-Espana A et al. Phase III study of capecitabine plus oxaliplatin versus continuous-infusion fluorouracil plus oxaliplatin as first-line therapy in metastatic colorectal cancer: final report of the Spanish Cooperative Group for the Treatment of Digestive Tumors Trial. J. Clin. Oncol.25, 4224–4230 (2007).
   PubMed Web of Science ®Google Scholar
• Iyer L RM. Clinical pharmacology of camptothecins. Cancer Chemother. Pharmacol.42(0), S31–S43 (1998).
   PubMed Web of Science ®Google Scholar
• Mathijssen RHJ, van Alphen RJ, Verweij J et al. Clinical Pharmacokinetics and Metabolism of Irinotecan (CPT-11). Clin. Cancer Res.7(8), 2182–2194 (2001).
   PubMed Web of Science ®Google Scholar
• Iyer L, Das S, Janisch L et al. UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity. Pharmacogenomics J.2, 43–47 (2002).
   PubMedGoogle Scholar
• Ando Y, Saka H, Asai G et al. UGT1A1 genotypes and glucuronidation of SN-38, the active metabolite of irinotecan. Ann. Oncol.9(8), 845–847 (1998).
   PubMed Web of Science ®Google Scholar
• Innocenti F, Undevia SD, Iyer L et al. Genetic Variants in the UDP-glucuronosyltransferase 1a1 gene predict the risk of severe neutropenia of irinotecan. J. Clin. Oncol.22(8), 1382–1388 (2004).
   PubMed Web of Science ®Google Scholar
• Rougier P, Van Cutsem E, Bajetta E et al. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet352(9138), 1407–1412 (1998).
   PubMed Web of Science ®Google Scholar
• Michael M HD, Oza A, et al. The palliative benefit of irinotecan in 5-fluorouracil-refractory colorectal cancer: its prospective evaluation by a Multicenter Canadian Trial. Clin. Colorectal Cancer2, 93–101 (2002).
   PubMedGoogle Scholar
• Douillard JY, Cunningham D, Roth AD et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet355(9209), 1041–1047 (2000).
   PubMed Web of Science ®Google Scholar
• Tournigand C, Andre T, Achille E et al. FOLFIRI Followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR Study. J. Clin. Oncol.22(2), 229–237 (2004).
   PubMed Web of Science ®Google Scholar
• C. Fuchs JM, E. Mitchell, R.Wierzbicki et al. A randomized trial of first-line irinotecan/fluoropymidine combinations with or without celecoxib in metastatic colorectal cancer (BICC-C). 2006 ASCO Annual Meeting Proceedings Part I. J. Clin. Oncol.24(18 Suppl.) (2006) (Abstract 3506).
   Google Scholar
• Saltz LB, Cox JV, Blanke C et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N. Engl. J. Med.343(13), 905–914 (2000).
   PubMed Web of Science ®Google Scholar
• Delaunoit R GR, Sargent DJ et al. Mortality associated with daily bolus 5-fluorouracil/leucovorin administered in combination with either irinotecan or oxaliplatin. Cancer101(10), 2170–2176 (2004).
   PubMed Web of Science ®Google Scholar
• Sargent DJ ND, O’Connell MJ, Schilsky RL. Recommendation for caution with irinotecan, fluorouracil, and leucovorin for colorectal cancer. N. Engl. J. Med.345(2), 144–145 (2001).
   PubMed Web of Science ®Google Scholar
• Goldberg RM, Sargent DJ, Morton RF et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J. Clin. Oncol.22(1), 23–30 (2004).
   PubMed Web of Science ®Google Scholar
• Colucci G, Gebbia V, Paoletti G et al. Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell’Italia Meridionale. J. Clin. Oncol.23(22), 4866–4875 (2005).
   PubMed Web of Science ®Google Scholar
• Grothey A, Jordan K, Kellner O et al. Randomized phase II trial of capecitabine plus irinotecan (CapIri) vs capecitabine plus oxaliplatin (CapOx) as first-line therapy of advanced colorectal cancer (ACRC). Proc. Am. Soc. Clin. Oncol.22, 255 (2003) (Abstract 1022).
   Google Scholar
• Vauthey J-N, Pawlik TM, Ribero D et al. chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J. Clin. Oncol.24(13), 2065–2072 (2006).
   PubMed Web of Science ®Google Scholar
• Grothey A, Sargent D, Goldberg RM et al. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J. Clin. Oncol.22(7), 1209–1214 (2004).
   PubMed Web of Science ®Google Scholar
• Grothey A, Sargent D. Overall survival of patients with advanced colorectal cancer correlates with availability of fluorouracil, irinotecan, and oxaliplatin regardless of whether doublet or single-agent therapy is used first line. J. Clin. Oncol.23(36), 9441–9442 (2005).
   PubMed Web of Science ®Google Scholar
• Lynch JP, Rustgi AK. Mechanisms of GI malignancies. In: Physiology of the Gastrointestinal Tract. Johnson L (Ed.). Elsevier, CA, USA (2004).
   Google Scholar
• Hanahan D, Weinberg RA. The hallmarks of cancer. Cell100(1), 57–70. (2000).
   PubMed Web of Science ®Google Scholar
• Folkman J. Angiogenesis: an organizing principle for drug discovery? Nat. Rev. Drug Discov.6(4), 273–286 (2007).
   PubMed Web of Science ®Google Scholar
• Easwaran V, Lee SH, Inge L et al. β-catenin regulates vascular endothelial growth factor expression in colon cancer. Cancer Res.63(12), 3145–3153 (2003).
   PubMed Web of Science ®Google Scholar
• Gerber H-P, Ferrara N. Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res.65(3), 671–680 (2005).
   PubMed Web of Science ®Google Scholar
• Kabbinavar F, Hurwitz HI, Fehrenbacher L et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J. Clin. Oncol.21(1), 60–65 (2003).
   PubMed Web of Science ®Google Scholar
• Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med.350(23), 2335–2342 (2004).
   PubMed Web of Science ®Google Scholar
• Giantonio BJ, Catalano PJ, Meropol NJ et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J. Clin. Oncol.25(12), 1539–1544 (2007).
   PubMed Web of Science ®Google Scholar
• Cassidy J, Clarke S, Diaz-Rub E et al. XELOX vs FOLFOX4: Efficacy results from XELOX-1/NO16966, a randomized Phase III trial in first-line metastatic colorectal cancer (MCRC). J. Clin. Oncol.25(18 Suppl.) (2007) (Abstract 4030).
   PubMedGoogle Scholar
• Saltz L, Clarke S, Diaz-Ru E et al. Bevacizumab (Bev) in combination with XELOX or FOLFOX4: updated efficacy results from XELOX-1/NO16966, a randomized Phase III trial in first-line metastatic colorectal cancer. J. Clin. Oncol.25(18 Suppl.) (2007) (Abstract 4028).
   Google Scholar
• Scappaticci FA, Skillings JR, Holden SN et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J. Natl Cancer Inst.99(16), 1232–1239 (2007).
   PubMed Web of Science ®Google Scholar
• Los M, Roodhart JM, Voest EE. Target practice: lessons from Phase III trials with bevacizumab and vatalanib in the treatment of advanced colorectal cancer. Oncologist12(4), 443–450 (2007).
   PubMed Web of Science ®Google Scholar
• Allen JA, Adlakha A, Bergethon PR. Reversible posterior leukoencephalopathy syndrome after bevacizumab/FOLFIRI regimen for metastatic colon cancer. Arch. Neurol.63(10), 1475–1478 (2006).
   PubMed Web of Science ®Google Scholar
• Goldberg RM. Cetuximab. Nat. Rev. Drug Discov. (Suppl.), S10–11 (2005).
   Google Scholar
• Kopp R, Rothbauer E, Ruge M et al. Clinical implications of the EGF receptor/ligand system for tumor progression and survival in gastrointestinal carcinomas: evidence for new therapeutic options.Recent Results Cancer Res.162, 115–132 (2003).
   PubMedGoogle Scholar
• Galizia G, Lieto E, Ferraraccio F et al. Prognostic significance of epidermal growth factor receptor expression in colon cancer patients undergoing curative surgery. Ann. Surg. Oncol.13(6), 823–835 (2006).
   PubMed Web of Science ®Google Scholar
• Saltz LB, Meropol NJ, Loehrer PJ Sr. et al. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J. Clin. Oncol.22(7), 1201–1208 (2004).
   PubMed Web of Science ®Google Scholar
• Cunningham D, Humblet Y, Siena S et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N. Engl. J. Med.351(4), 337–345 (2004).
   PubMed Web of Science ®Google Scholar
• Lenz HJ, Van Cutsem E, Khambata-Ford S et al. Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines. J. Clin. Oncol.24(30), 4914–4921 (2006).
   PubMed Web of Science ®Google Scholar
• Chung KY, Shia J, Kemeny NE et al. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J. Clin. Oncol.23(9), 1803–1810 (2005).
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Nowacki M, La I et al. Randomized Phase III study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): the CRYSTAL trial. J. Clin. Oncol.25(18 Suppl.) (2007) (Abstract 4000).
   Google Scholar
• Bokemeyer C, Bondarenko I, Makhs A et al. Cetuximab plus 5-FU/FA/oxaliplatin (FOLFOX-4) versus FOLFOX-4 in the first-line treatment of metastatic colorectal cancer (mCRC): OPUS, a randomized Phase II study. 2007 ASCO Annual Meeting Proceedings Part I. J. Clin. Oncol.25(18 Suppl.) 4035, (2007).
   Google Scholar
• Saif MW, Kim R. Incidence and management of cutaneous toxicities associated with cetuximab. Expert Opin. Drug Saf.6(2), 175–182 (2007).
   Google Scholar
• Tejpar S, Peeters M, Humb Y et al. Phase I/II study of cetuximab dose-escalation in patients with metastatic colorectal cancer (mCRC) with no or slight skin reactions on cetuximab standard dose treatment (EVEREST): pharmacokinetic (PK), pharmacodynamic (PD) and efficacy data. 2007 ASCO Annual Meeting Proceedings Part I. J. Clin. Oncol.25(18 Suppl.) 4037, (2007).
   Web of Science ®Google Scholar
• Saltz LB, Lenz H-J, Kindler HL et al. Randomized Phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study. J. Clin. Oncol.25(29), 4557–4561 (2007).
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Peeters M, Siena S et al. Open-label Phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J. Clin. Oncol.25(13), 1658–1664 (2007).
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Siena S, Humblet Y et al. An open-label, single-arm study assessing safety and efficacy of panitumumab in patients with metastatic colorectal cancer refractory to standard chemotherapy. Ann. Oncol.19(1), 92–98 (2007).
   PubMed Web of Science ®Google Scholar
• Baselga J, Tabernero J. Combined antiangiogenesis and antiepidermal growth factor receptor targeting in the treatment of cancer: hold back, we are not there yet. J. Clin. Oncol.25(29), 4516–4518 (2007).
   PubMedGoogle Scholar
• Rosell R, Taron M, Reguart N, Isla D, Moran T. Epidermal growth factor receptor activation: how exon 19 and 21 mutations changed our understanding of the pathway. Clin. Cancer Res.12(24), 7222–7231 (2006).
   PubMedGoogle Scholar
• Braun AH, Stark K, Dirsch O et al. The epidermal growth factor receptor tyrosine kinase inhibitor gefitinib sensitizes colon cancer cells to irinotecan. Anticancer Drugs16(10), 1099–1108 (2005).
   PubMedGoogle Scholar
• Fichera A, Little N, Jagadeeswaran S et al. Epidermal growth factor receptor signaling is required for microadenoma formation in the mouse azoxymethane model of colonic carcinogenesis. Cancer Res.67(2), 827–835 (2007).
   PubMedGoogle Scholar
• Kuo T, Cho CD, Halsey J et al. Phase II study of gefitinib, fluorouracil, leucovorin, and oxaliplatin therapy in previously treated patients with metastatic colorectal cancer. J. Clin. Oncol.23(24), 5613–5619 (2005).
   PubMed Web of Science ®Google Scholar
• Blanke CD. Gefitinib in colorectal cancer: if wishes were horses. J. Clin. Oncol.23(24), 5446–5449 (2005).
   PubMed Web of Science ®Google Scholar
• Schiffer CA. BCR-ABL tyrosine kinase inhibitors for chronic myelogenous leukemia. N. Engl. J. Med.357(3), 258–265 (2007).
   PubMed Web of Science ®Google Scholar
• Chow LQ, Eckhardt SG. Sunitinib: from rational design to clinical efficacy. J. Clin. Oncol.25(7), 884–896 (2007).
   PubMed Web of Science ®Google Scholar
• Stahtea XN, Roussidis AE, Kanakis I et al. Imatinib inhibits colorectal cancer cell growth and suppresses stromal-induced growth stimulation, MT1-MMP expression and pro-MMP2 activation. Int. J. Cancer (2007).
   PubMedGoogle Scholar
• Kitadai Y, Sasaki T, Kuwai T et al. Targeting the expression of platelet-derived growth factor receptor by reactive stroma inhibits growth and metastasis of human colon carcinoma. Am. J. Pathol.169(6), 2054–2065 (2006).
   PubMedGoogle Scholar
• Marzola P, Degrassi A, Calderan L et al. Early antiangiogenic activity of SU11248 evaluated in vivo by dynamic contrast-enhanced magnetic resonance imaging in an experimental model of colon carcinoma. Clin. Cancer Res.11(16), 5827–5832 (2005).
   PubMed Web of Science ®Google Scholar
• Morimoto AM, Tan N, West K et al. Gene expression profiling of human colon xenograft tumors followingtreatment with SU11248, a multitargeted tyrosine kinase inhibitor. Oncogene23(8), 1618–1626 (2004).
   PubMed Web of Science ®Google Scholar
• Saltz LB RL, Marshall JL et al. Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy. J. Clin. Oncol.25(30), 4793–4799 (2007).
   PubMed Web of Science ®Google Scholar
• Kohne C, Bajetta E, Lin E et al. Final results of CONFIRM 2: a multinational, randomized, double-blind, Phase III study in 2nd line patients (pts) with metastatic colorectal cancer (mCRC) receiving FOLFOX4 and PTK787/ZK 222584 (PTK/ZK) or placebo. Proceedings of the 2007 ASCO Annual Meeting. J. Clin. Oncol.25(18 Suppl.), 4033 (2007).
   PubMedGoogle Scholar
• Milano A, Iaffaioli RV, Caponigro F. The proteasome: a worthwhile target for the treatment of solid tumours? Eur. J. Cancer43(7), 1125–1133 (2007).
   Google Scholar
• Boccadoro M, Morgan G, Cavenagh J. Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapy. Cancer Cell Int.5(1), 18 (2005).
   PubMed Web of Science ®Google Scholar
• Zhu H, Guo W, Zhang L et al. Proteasome inhibitors-mediated TRAIL resensitization and Bik accumulation. Cancer Biol. Ther.4(7), 781–786 (2005).
   PubMed Web of Science ®Google Scholar
• Cusack JC, Jr, Liu R, Xia L et al. NPI-0052 enhances tumoricidal response to conventional cancer therapy in a colon cancer model. Clin. Cancer Res.12(22), 6758–6764 (2006).
   PubMedGoogle Scholar
• Watanabe T, Wu T-T, Catalano PJ et al. Molecular predictors of survival after adjuvant chemotherapy for colon cancer. N. Engl. J. Med.344(16), 1196–1206 (2001).
   PubMed Web of Science ®Google Scholar
• Genuardi M, Viel A, Bonora D et al. Characterization of MLH1 and MSH2 alternative splicing and its relevance to molecular testing of colorectal cancer susceptibility. Hum. Genet.102(1), 15–20 (1998).
   PubMedGoogle Scholar
• de la Chapelle A. Microsatellite instability. N. Engl. J. Med.349(3), 209–210 (2003).
   PubMed Web of Science ®Google Scholar
• Ribic CM, Sargent DJ, Moore MJ et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N. Engl. J. Med.349(3), 247–257 (2003).
   PubMed Web of Science ®Google Scholar
• Vogelstein B FE, Hamilton SR et al. Genetic alterations during colorectal-tumor development. N. Engl. J. Med.319(9), 525–532 (1988).
   PubMed Web of Science ®Google Scholar
• Ookawa K SM, Hiroshi S et al. Concordant p53 and DCC alterations and allelic losses on chromosomes 13q and 14q associated with liver metastases of colorectal carcinoma. Int. J. Cancer53(3), 385–387 (1993).
   Google Scholar
• Cho KR FE. DCC: linking tumor suppressor genes and altered cell surface interactions in cancer? Curr. Opin. Genet. Dev.5(1), 72–78 (1995).
   PubMedGoogle Scholar
• Jen J, Kim H, Piantadosi S et al. Allelic loss of chromosome 18q and prognosis in colorectal cancer. N. Engl. J. Med.331(4), 213–221 (1994).
   PubMed Web of Science ®Google Scholar
• Ogunbiyi OA, Goodfellow PJ, Herfarth K et al. Confirmation that chromosome 18q allelic loss in colon cancer is a prognostic indicator. J. Clin. Oncol.16(2), 427–433 (1998).
   PubMed Web of Science ®Google Scholar
• Liersch T, Langer C, Ghadimi BM et al. Lymph node status and TS gene expression are prognostic markers in Stage II/III rectal cancer after neoadjuvant fluorouracil-based chemoradiotherapy. J. Clin. Oncol.24(25), 4062–4068 (2006).
   PubMed Web of Science ®Google Scholar
• Prcolo VE FS, Hansen K et al. Mutated p53 gene is an independent adverse predictor of survival in colon carcinoma. Arch. Surg.132(4), 371–375 (1997).
   PubMedGoogle Scholar
• Ahnen DJ, Feigl P, Quan G et al.Ki-ras mutation and p53 overexpression predict the clinical behavior of colorectal cancer: a Southwest Oncology Group study. Cancer Res.58(6), 1149–1158 (1998).
   PubMed Web of Science ®Google Scholar
• Barrier A, Roser F, Boelle PY et al. Prognosis of Stage II colon cancer by non-neoplastic mucosa gene expression profiling. Oncogene26(18), 2642–2648 (2006).
   PubMedGoogle Scholar
• Zhao Z XY, Elson P et al. Plasma lysophosphatidylcholine levels: potential biomarkers for colorectal cancer. J. Clin. Oncol.25(19), 2696–2701 (2007).
   PubMed Web of Science ®Google Scholar
• Khambata-Ford S, Garrett CR, Meropol NJ et al. Expression of epiregulin and amphiregulin and K-ras Mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J. Clin. Oncol.25(22), 3230–3237 (2007).
   PubMed Web of Science ®Google Scholar
• Benson AB, III. New approaches to assessing and treating early-stage colon and rectal cancers: Cooperative Group strategies for assessing optimal approaches in early-stage disease. Clin. Cancer Res.13(22), 6913–6920 (2007).
   PubMedGoogle Scholar